Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy | Vertex Pharmaceuticals Newsroom Vertex PharmaceuticalsVertex shares pop after nonopioid painkiller posts…